Business
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacyData showed a rapid onset of action, peak effect superior to placebo, and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity at Week 24Data to be presented at upcom
About this update from Ipsen Sa
[{"type":"image","alt":"Ipsen Pharma","displaySize":"","headline":null,"caption":"Ipsen Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/89RavcsKEHEdDt270X336Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eb628cc0e353381e6b738c556a0e31","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IPN10200 is a recombinant, first-in-class molecule uniquely engineered to generate increased receptor affinity and internalization that produces a longer duration of action, optimized for safety and efficacy","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Data showed a rapid onset of action, peak effect superior to placebo, and a substantial majority of patients experiencing clinically significant longer duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity at Week 24","length":264,"tagName":"p"}]},{"val":[{"type":"text","content":"Data to be presented at upcoming scientific conference in H1 2026 and Phase III start-up activities initiated","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase II development continues for therapeutic indications including adult upper limb spasticity, migraine and cervical dystonia","length":128,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":708,"olType":false},{"type":"text","content":"PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200 showed a statistically significant improvement in response at Week 4 vs placebo (primary endpoint). A longer duration of effect was also observed with a substantial majority of patients experiencing a clinically significant response at Week 24 compared with placebo and Dysport, defined as a score of “none” or “mild”. IPN10200 continued to show a greater response in line severity vs Dysport at Week 36. In this trial Dysport was shown to perform consistently with its profile.","length":752,"tagName":"p"},{"type":"te...